1-(2-二苯基甲氧基乙基)-4-(3-苯基丙基)哌嗪双盐酸盐 | 67469-81-2

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-二苯基甲氧基乙基)-4-(3-苯基丙基)哌嗪双盐酸盐
• 英文名称: GBR 12935 dihydrochloride
• 英文别名: 1-(2-benzhydryloxyethyl)-4-(3-phenylpropyl)piperazine;dihydrochloride
• CAS: 67469-81-2
• 化学式: C28H36Cl2N2O
• mdl: MFCD00083175
• 分子量: 487.5
• InChiKey: NQWRSILGEXNJIT-UHFFFAOYSA-N

物化性质

• 溶解度：
  H2O：20 mg/mL 加热

计算性质

• 辛醇/水分配系数(LogP)：
  5.96
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  15.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Small organic molecule regulators of cell proliferation
  申请人：Brunton Shirley Ann

  公开号：US20080182859A1

  公开（公告）日：2008-07-31

  The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal patched pathway or agonizing smoothened or hedgehog activity.

  本发明提供了一种调节细胞或组织增殖或分化的方法和试剂，包括将细胞与化合物接触。在某些实施例中，该方法和试剂可用于纠正或抑制异常或不需要的生长状态，例如通过拮抗正常的Patched途径或激活Smoothened或Hedgehog活性。
• SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION
  申请人：Brunton Shirley Ann

  公开号：US20120245184A1

  公开（公告）日：2012-09-27

  The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal patched pathway or agonizing smoothened or hedgehog activity.

  本发明提供了一种调节细胞或组织增殖或分化的方法和试剂，包括将细胞与化合物接触。在某些实施例中，这些方法和试剂可用于纠正或抑制异常或不良的生长状态，例如通过拮抗正常的Patched通路或激活Smoothened或Hedgehog活性。
• Use of an amphetamine composition for regulating memory consolidation
  申请人：Cognition Pharmaceuticals LLC

  公开号：EP1743631A2

  公开（公告）日：2007-01-17

  The invention relates to the use of an amphetamine composition comprising one or more amphetamine compounds and enantiomerically enriched in an 1-amphetamine or in an 1-methamphetamine, for the manufacture of a medicament for improving memory consolidation in a human having an impairment in memory consolidation. The composition comprises at least 51 mole percent 1-amphetamine or 1-methamphetamine, relative to total amphetamine content of the composition. The invention makes available methods and reagents for enhancing and/or restoring long-term memory function and performance, e.g. to improve long-term memory (LTM) and recall ability in animal subjects.

  本发明涉及一种安非他明组合物的用途，该组合物包含一种或多种安非他明化合物，并且对映体富含1-安非他明或1-甲基安非他明，用于制造改善记忆巩固功能受损的人的记忆巩固功能的药物。相对于组合物中苯丙胺的总含量，该组合物包含至少 51 摩尔%的 1-苯丙胺或 1-甲基苯丙胺。本发明提供了增强和/或恢复长期记忆功能和表现的方法和试剂，例如，改善动物的长期记忆（LTM）和回忆能力。
• Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
  申请人：Sepracor Inc.

  公开号：EP2343073A2

  公开（公告）日：2011-07-13

  One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.

  本发明的一个方面涉及含有两种或两种以上活性剂的药物组合物，这些活性剂一起服用时可用于治疗失眠和/或抑郁症等。药物组合物的第一种成分是 GABA 受体调节化合物。药物组合物的第二种成分是血清素再摄取抑制剂、去甲肾上腺素再摄取抑制剂、5-HT2A调节剂或多巴胺再摄取抑制剂。在某些实施方案中，药物组合物包含艾佐匹克隆。在一个优选的实施方案中，药物组合物包括艾司佐匹克隆和氟西汀。本发明还涉及一种治疗睡眠异常、治疗失眠、治疗抑郁症、增强抗抑郁治疗、引起剂量节省效应、减少抑郁症复发、改善抗抑郁治疗的疗效或改善抗抑郁治疗的耐受性的方法，包括向有需要的患者联合施用GABA受体调节化合物；和SRI、NRI、5-HT2A调节剂或DRI。
• Use of threo-methylphenidate compounds to enhance memory
  申请人：——

  公开号：US20020103162A1

  公开（公告）日：2002-08-01

  The present invention makes available methods and reagents for facilitating memory, e.g., to increase memory function such as long-term memory and recall ability.

  本发明提供了促进记忆的方法和试剂，例如，增加记忆功能，如长期记忆和回忆能力。